Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00056082 · ClinicalTrials.gov registry record · Phase 2
Celecoxib in Preventing Breast Cancer in At-Risk Premenopausal Women
A Phase 2 study, sponsored by University of Kansas Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 110
- Enrollment target
NCT00056082 is a Phase 2 study that has completed, run by University of Kansas Medical Center. The registered enrollment target is 110 participants.
The verdict
NCT00056082, a Phase 2 study, has completed, sponsored by University of Kansas Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 110 participants
- Enrollment target
Study Summary
RATIONALE: Chemoprevention therapy uses certain drugs to try to prevent the development or recurrence of cancer. Celecoxib may be effective in preventing breast cancer in at-risk women. PURPOSE: Phase II trial to study the effectiveness of celecoxib in preventing breast cancer in premenopausal women who are at risk of developing cancer.
Interventions
- DRUG celecoxib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 110 participants |
| Start Date | 2003-01 |
| Est. Completion | 2013-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00056082
The ClinicalTrials.gov registry entry for NCT00056082 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 110 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Kansas Medical Center, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which celecoxib is the first listed.
NCT00056082 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00056082 about?
NCT00056082 is a clinical study titled "Celecoxib in Preventing Breast Cancer in At-Risk Premenopausal Women". RATIONALE: Chemoprevention therapy uses certain drugs to try to prevent the development or recurrence of cancer. Celecoxib may be effective in preventing breast cancer in at-risk women. PURPOSE: Phase II trial to study the effectiveness of celecoxib in preventing breast cancer in premenopausal wome...
What is the current status of trial NCT00056082?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 110 participants. The study started on 2003-01. Estimated completion is 2013-07.
What interventions are being tested in trial NCT00056082?
The interventions under investigation include: celecoxib (DRUG).
Who is sponsoring clinical trial NCT00056082?
This trial is sponsored by University of Kansas Medical Center, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.